EDITORIAL SECTION

Articles

Bispecific Antibodies: Transforming the Future of Oncology

For two decades bispecific antibodies occupied an awkward position in pharmaceutical oncology strategy scientifically compelling commercially unproven and persistently difficult to manufacture That characterisation no longer holds Nineteen bispecific antibodies have been approved globally and combined sales of the class passed twelve billion dollars in with several products now anchoring

Manufacturing mRNA, Cell, and Gene Therapies at Commercial Scale

Why Cell and Gene Therapies Fail in Europe After the Science Has Already Worked The uncomfortable statistic for anyone financing advanced therapies in Europe is not the clinical attrition rate It is the withdrawal rate after approval An analysis of advanced therapy medicinal products granted European marketing authorisation found that roughly one in five had subsequently been withdrawn and of th...

Personalized Medicine and Longevity: Advancing the Frontier

The world is experiencing a profound demographic shift with population aging impacting healthcare economies and human rights The United Nations projects that by the number of people aged and over will double to billion comprising one in six people worldwide United Nations OHCHR By older adults will likely outnumber children necessitating a rethink of health aging and longevity Hartmann Young

Market Access Strategies for Pharma Products in Europe: A Comprehensive Guide

The European pharmaceutical market is dynamic and diverse presenting both opportunities and challenges for companies seeking market access This guide delves into effective strategies for navigating the complexities of market access in Europe focusing on key aspects such as reimbursement pricing and overcoming market entry challenges

Fostering Pharma Collaboration: Challenges & Opportunities

In the everevolving world of pharmaceuticals fostering collaboration is essential for driving innovation and meeting the diverse needs of patients However this seemingly simple goal is often hindered by numerous challenges

Cell and Gene Therapy's Trillion-Dollar Reckoning Is Here

Cell and gene therapies can cure diseases once thought untreatable Yet a string of commercial collapses now suggests that curing the patient and sustaining the business are two very different challenges and the industry is confronting the gap at last

Techno Trends

University of Dundee’s Cabamiquine Shows Promise for Single-Dose Malaria Treatment

Researchers at the University of Dundee have reported encouraging clinical results for cabamiquine a novel antimalarial compound being developed as a potential singledose treatment for malaria

Projects

Genentech to Invest US$750 Million in Oregon Device Fill-Finish Facility

Genentech a member of the Roche Group plans to invest approximately US million in a new device fillfinish manufacturing facility at its acre campus in Hillsboro Oregon The project will add endtoend manufacturing

Research Insights

One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases

Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys